Progestin-only pills (POPs) for contraception
- Andrew M Kaunitz, MD
Andrew M Kaunitz, MD
- Professor and Associate Chairman
- Department of Obstetrics and Gynecology
- University of Florida College of Medicine-Jacksonville
Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. In addition to progestin-only pills, other types of progestin-only contraceptives include:
●Progestin injections (see "Depot medroxyprogesterone acetate for contraception")
●Progestin implants (eg, Nexplanon, Jadelle) (see "Etonogestrel contraceptive implant")
●Intrauterine contraception (eg, Mirena, Skyla) (see "Intrauterine contraception: Devices, candidates, and selection")
Norethindrone — Only one progestin-only contraceptive pill (POP) formulation is marketed in the United States: norethindrone 0.35 mg tablets (Micronor, Nor-QD, and generics). The progestin dose is substantially lower than the dose in any combination oral contraceptive. It is dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week) . Unless otherwise noted, the information on POPs in this topic primarily applies to norethindrone POPs.
- Kaunitz AM. Revisiting progestin-only OCs. Contemp Ob Gyn 1997; 91.
- Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003; 997:163.
- Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception 2005; 71:8.
- Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care 2008; 34:237.
- Speroff L, Darney P. A Clinical Guide for Contraception, 4th ed, Williams and Wilkins, Baltimore 2005.
- Lebech PE, Svendsen PA, Ostergaard E, Koch F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48:Suppl 3:22+.
- Wright SW, Fotherby K, Fairweather F. Effect of daily small doses of Norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77:65.
- Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397.
- Vessey MP, Lawless M, Yeates F, et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10:117.
- Dunson TR, McLaurin VL, Grubb GS, Rosman AW. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 1993; 47:23.
- Guillebaud J. Contraception: Your Questions Answered, 2nd ed, Churchill Livingstone Elsevier, New York 1993.
- Simon JA, Wysocki S, Brandman J, Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003; 10:37.
- Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
- Brenner PF, Mishell DR Jr, Stanczyk FZ, Goebelsmann U. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 1977; 129:133.
- Stanczyk FZ, Brenner PF, Mishell DR Jr, et al. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978; 18:615.
- Weiner E, Victor A, Johansson ED. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14:563.
- Steenland MW, Rodriguez MI, Marchbanks PA, Curtis KM. How does the number of oral contraceptive pill packs dispensed or prescribed affect continuation and other measures of consistent and correct use? A systematic review. Contraception 2013; 87:605.
- Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92:1003.
- Lopez LM, Edelman A, Chen M, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev 2013; :CD008815.
- MacGregor EA. Contraception and headache. Headache 2013; 53:247.
- Belsey EM. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988; 38:181.
- Broome M, Fotherby K. Clinical experience with the progestogen-only pill. Contraception 1990; 42:489.
- McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50:S1.
- Shoupe D, Horenstein J, Mishell DR Jr, et al. Characteristics of ovarian follicular development in Norplant users. Fertil Steril 1991; 55:766.
- Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42:51.
- Maximizing the use of the progestin minipill. Contracept Technol Update 1999; 20:19.
- Fotherby K. The progestogen-only pill and thrombosis. Br J Fam Plann 1989; 15:83.
- Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44:223.
- Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69:89.
- Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375.
- Winkler UH. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57:203.
- Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.
- Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4:67.
- Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.
- Lidegaard Ø, Løkkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.
- Bergendal A, Persson I, Odeberg J, et al. Association of venous thromboembolism with hormonal contraception and thrombophilic genotypes. Obstet Gynecol 2014; 124:600.
- ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.
- Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016; 65:1.
- Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.
- Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.
- Caird LE, Reid-Thomas V, Hannan WJ, et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf) 1994; 41:739.
- Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.
- Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54:1S.
- World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 5th Edition, World Health Organization, 2015.
- MECHANISM OF ACTION
- Candidates for use of POPs
- - Women in whom estrogen is contraindicated
- Patient evaluation
- Timing doses and missed pills
- Reducing barriers to use
- SIDE EFFECTS
- RISKS AND BENEFITS
- Effect on cardiovascular risk
- Effect on carbohydrate metabolism
- Ectopic pregnancy risk
- Effect on bone mineral density
- Older reproductive age women
- Effect on cancer risk
- Effect on sexually transmitted infections
- Noncontraceptive benefits
- USE AFTER ABORTION OR DELIVERY
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS